Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Project Information

MindTrack

Grant agreement ID: 885458

DOI

10.3030/885458

Project closed

EC signature date 22 November 2019

Start date 1 November 2019

End date 30 April 2020

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

BRAINGAZE SL
Spain

Periodic Reporting for period 1 - MindTrack (Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders)

Reporting period: 2019-11-01 to 2020-04-30

Summary of the context and overall objectives of the project

Alzheimer’s disease is one of the leading causes of ill-health and disability globally and will continue increasing due to growing aging populations, with high level of social and economic burden. Currently, there are no single solutions to objectively diagnose this disorder. BRAINGAZE has develop MindTrack, which is a unique patented, scientifically validated biomarker-based decision support system for the early and objective diagnosis of cognitive disorders. MindTrack has shown 92% accuracy in the detection of Attention Deficit Hyperactivity Disorder (ADHD) in children and adults. This application is already being commercialized. With this project, we aim at expanding MindTrack potential to other novel application: Alzheimer’s disease early diagnosis

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Thanks to the Feasibility Study, we have been able to establish the conditions for the realization of a clinical trial for the validation of this new application as well as know our target market in depth, built our value chain (identifying partners and distributors and main competitors) and perform realistic financial projections.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Traditionally, clinicians have used a variety of approaches, mainly semi-structured interviews and their own expertise for the diagnosis of Alzheimer’s disease. In these last few years, neuroimaging techniques have been also employed. However, these tools present important drawbacks: they are only used once the patient has developed noticeable symptoms (and thus, the disease is in a more advanced developmental stage), interviews are partially subjective and time-consuming and neuroimaging techniques are costly and invasive. MindTrack is a non-invasive, robust and quick method for the early and accurate diagnosis of Alzheimer’s disease. Based on a neural biomarker, MindTrack supports clinicians during the diagnostic process, enabling patients to know their probability of having the disorder up to 10 years before the first symptoms arise and take action.

Company logo